The role of BRCA1 and BRCA2 in the repair of double-strand breaks (DSBs) is thought to be central to their tumour-suppressor activities, and underlies the hypersensitivity of Brca-deficient cells to DNAdamaging agents. While cisplatin and PARP inhibitors (PARPi) have been shown to be effective chemotherapeutic agents, most Brca-mutant carcinomas acquire resistance 1 . Besides reduced uptake and increased efflux of drugs, the most well-described mechanism that drives chemo therapeutic resistance in Brca1/2-deficient tumours is through the restoration of homologous recombination (HR) 1 . Identification of additional mechanisms underlying resistance to DNA damage is crucial for improving therapies and predicting tumour responses in Brca-deficient cancers. number of chromosomal aberrations in Brca2 −/− cells challenged with HU (Extended Data Fig. 3b ), suggesting that PTIP has functions at Cells deficient in the Brca1 and Brca2 genes have reduced capacity to repair DNA double-strand breaks by homologous recombination and consequently are hypersensitive to DNA-damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors. Here we show that loss of the MLL3/4 complex protein, PTIP, protects Brca1/2-deficient cells from DNA damage and rescues the lethality of Brca2-deficient embryonic stem cells. However, PTIP deficiency does not restore homologous recombination activity at double-strand breaks. Instead, its absence inhibits the recruitment of the MRE11 nuclease to stalled replication forks, which in turn protects nascent DNA strands from extensive degradation. More generally, acquisition of PARP inhibitors and cisplatin resistance is associated with replication fork protection in Brca2-deficient tumour cells that do not develop Brca2 reversion mutations. Disruption of multiple proteins, including PARP1 and CHD4, leads to the same end point of replication fork protection, highlighting the complexities by which tumour cells evade chemotherapeutic interventions and acquire drug resistance.
PTIP loss protects RFs in Brca-deficient cells
In addition to their roles in HR, recent studies have uncovered DSBindependent functions for BRCA1 and BRCA2 during replication stress [2] [3] [4] [5] [6] . Since MRE11 has been implicated in mediating replication fork (RF) degradation in cell lines [2] [3] [4] , we tested whether primary cells deficient in BRCA1 or BRCA2 also showed degradation of nascent replication tracts. We therefore conditionally inactivated BRCA1 and BRCA2 in B lymphocytes (Brca1 f/f CD19Cre; Brca2 f/f Cd19Cre). B cells were sequentially labelled with CldU-(red) followed by IdU-(green), after which the active RFs were stalled with hydroxyurea (HU) (Fig. 1a) . The relative shortening of the IdU tract after HU treatment serves as a measure of RF degradation (Fig. 1a ). Upon HU treatment, wild-type (WT) cells showed a mean IdU/CldU tract ratio close to 1 (Fig. 1b) . However, Brca1-and Brca2-deficient B cells exhibited a 30-45% reduction in the IdU tract length ( Consistent with previous data 2, 3 , RF degradation in B lymphocytes was dependent on MRE11 exonuclease activity (Extended Data Fig. 1a-c) . We also tested the role of DNA2 and the Werner syndrome helicase/nuclease (WRN) in degradation of forks in Brca2-deficient B cells. Treatment of Brca2-deficient cells with WRN inhibitor did not result in fork protection, whereas MRE11 and DNA2 were epistatic (Extended Data Fig. 1c ).
Since 53BP1, RIF1, and PTIP counteract BRCA1-dependent HR by inhibiting MRE11-dependent DSB resection [7] [8] [9] [10] [11] [12] [13] [14] [15] , we examined whether these factors might also function in RF stability. We thus inactivated BRCA1, BRCA2, RIF1, PTIP and 53BP1 in B lymphocytes (Extended Data Fig. 2a ). Short exposure to HU did not promote significant DSB formation (Extended Data Fig. 2b) , and fork progression rates were comparable across all genotypes (Extended Data Fig. 2c-f ).
Absence of 53BP1 did not protect Brca1-deficient B cells from degradation of RFs (Fig. 1b) , consistent with the finding that BRCA1 acts in RF stabilization in a manner independent of DSB repair 2, 3 . Nascent strands also shortened considerably in the absence of the 53BP1 effector Rif1 and in Brca1/Rif1 doubly deficient cells (Fig. 1c) . In striking contrast, loss of Ptip protected RFs from HU-induced degradation in both Brca1-and Brca2-deficient cells (Fig. 1d, e ). Moreover, while Brca1 −/− , Rif1 −/− , and Brca1 −/− Rif1 −/− B cells displayed increased genomic instability when treated with HU (Extended Data Fig. 3a ), Brca1/Ptip doubly deficient cells exhibited 2.4-fold fewer chromosomal aberrations and increased viability compared with Brca1 −/− (Fig. 1f) . Similarly, loss of Ptip decreased the ARTICLE RESEARCH stalled RFs distinct from its DSB-dependent interactions with 53BP1 and RIF1.
We hypothesized that HU-induced degradation would impact RF progression rates. We therefore assayed the ability of WT and mutant cells to incorporate nucleotide analogues in the presence of low concentrations of HU. We observed a significant decrease in IdU tract lengths during HU exposure across all genotypes. However, Brca2deficient cells had significantly decreased progression rates upon HU treatment, whereas Ptip −/− and Brca2 −/− Ptip −/− cells displayed significantly longer replication tracts (Extended Data Fig. 3c ). We also tested the effect of Ptip-deficiency on recovery after replication stalling with high concentrations of HU. We found that although the percentage of restarted RFs did not change among genotypes (Extended Data Fig. 3d ), loss of Brca2 resulted in a delayed restart, whereas Brca2/Ptip doubly deficient cells restarted normally (Extended Data Fig. 3e ). Thus, loss of PTIP promotes RF progression and timely restart in Brca2-deficient cells, which correlates with decreased RF degradation.
PTIP loss rescues lethality of Brca2-null ESCs
Since elevated levels or stabilized RAD51 filaments could protect RFs from degradation 2, 3, 16 , we asked whether PTIP deficiency leads to overexpression of RAD51 or enhanced RAD51 activity. RAD51 levels were similar in WT, Ptip −/− , Brca2 −/− , and Brca2 −/− Ptip −/− cells (Extended Data Fig. 3f ), but the ability of RAD51 to relocalize to sites of DNA DSBs was severely impaired in Brca2/Ptip-deficient B cells ( Fig. 1g and Extended Data Fig. 3g ) and embryonic stem cells (ESCs) (see Fig. 2c, d) . Moreover, loss of Ptip did not enhance the loading of RAD51 on nascent chromatin (see Fig. 3f ).
Loss of Brca2 in ESCs is incompatible with cell survival 17 . To test whether PTIP deficiency could promote ESC survival we knocked down PTIP in PL2F7 mouse ESCs, which have one null and one conditional allele of Brca2 (Brca2 f/− , Fig. 2a and Extended Data Fig. 4a ) 17 . After CRE transfection in Brca2 f/− ESCs and selection in HAT medium, very few resistant colonies were obtained and these remained Brca2 f/− rather than Brca2-null, reflecting the essential role of BRCA2 in ESC viability ( Fig. 2b) 17 . Strikingly, 12.5% and 5% of the HAT-resistant colonies were Brca2-null when targeted by Ptip short hairpin RNAs (shRNAs) 1 and 2 respectively ( Fig. 2b and Extended Data Fig. 4b ). Consistent with our analysis of Brca2 −/− Ptip −/− B cells ( Fig. 1g ), irradiation-induced RAD51 foci formation was defective in Brca2/Ptip-deficient ESCs (Fig. 2c, d ). Moreover, while efficient gene targeting to the Pim-1 locus was observed in WT ESCs using a promoterless hygromycin cassette (100% of the hygromycin-resistant WT clones were targeted integrations), we did not observe a single targeted clone in Brca2/Ptip-deficient ESCs ( Fig. 2e ) indicative of defective HR. Similarly, the synthetic HR reporter substrate DR-GFP revealed impaired HR in Brca2/Ptip-deficient ESCs (Extended Data Fig. 4c ). Nevertheless, stalled RFs in PTIP-deficient Brca2 −/− ESCs displayed RF protection compared with Brca2 hypomorphic mutant ESCs (Y3308X) 17 (Fig. 2f ). Thus, deficiency in PTIP protects RFs from degradation and rescues the lethality of Brca2 knockout ESCs without restoring DSB-induced HR.
BRCA2 is dispensable for HR at RFs
It has been suggested that HR at stalled forks is regulated differently from HR at DSBs 18 . As a readout for HR at RFs, we assayed for sister chromatid exchanges (SCEs) in WT and Y3308X ESCs. Although Y3308X cells show undetectable levels of irradiation-induced RAD51 formation and loss of targeted integration, indicative of a defect in DSB-induced HR 17 , the basal frequency of SCE was normal in Y3308X cells (Extended Data Fig. 4d ). Moreover, RAD51 was enriched on nascent DNA in Y3308X during normal replication and in presence of HU as measured by isolation of proteins on native DNA (iPOND) analysis (Extended Data Fig. 4e ). We also observed similar frequencies of spontaneously generated and DNA damage-induced SCEs in WT, Brca2-null and Brca2/Ptip-deficient B cells (Extended Data Fig. 4f ). Thus, in contrast to RAD51 which is required for DSB-and replication-associated HR 19 , BRCA2 appears to be dispensable for HR 
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that uses the nascent sister chromatid to repair DNA lesions during replication.
MRE11 association at RFs depends on PTIP-MLL3/4
Although the recruitment of PTIP to DSBs after irradiation is dependent on 53BP1 (Extended Data Fig. 5a , b) 10 , we hypothesized that PTIP might be recruited to sites of stalled RFs independently of its interactions with 53BP1. Consistently, we observed PTIP accumulation at sites of replication stalling marked by pan-nuclear γ-H2AX staining 20 . Among cells exhibiting pan γ-H2AX signal, 71.4% of WT and 78% of 53Bp1 −/− mouse embryonic fibroblasts (MEFs) exhibited PTIP foci following HU treatment ( Fig. 3a and Extended Data Fig. 5c ). Even in the absence of HU treatment, PTIP exhibited extensive co-localization with proliferating cell nuclear antigen (PCNA) during late S phase both in WT and in 53Bp1-deficient cells ( Fig. 3b and Extended Data Fig. 5d, e ). Collectively, these data suggest that PTIP might function during normal or perturbed replication in a DSB-and 53BP1independent manner.
Like PTIP, MRE11 also associates with chromatin in a DNA damageindependent but DNA replication-dependent manner 21 (Fig. 3c ). Loss of PTIP resulted in a marked decrease of MRE11 association with PCNA foci in unperturbed cycling MEFs ( Fig. 3c ) and defective MRE11 recruitment to ssDNA regions upon HU treatment (Extended Data Fig. 5f ). Re-introduction of WT full-length PTIP into Ptip −/− MEFs restored MRE11 co-localization with PCNA in late S phase ( Fig. 3d ). Thus, in contrast to irradiation-induced MRE11 foci, localization of MRE11 to sites of DNA replication is PTIP-dependent ( Fig. 3c -e and Extended Data Fig. 5g ).
To monitor MRE11 and RAD51 association with active and stalled RFs we performed iPOND analysis in WT and Ptip −/− MEFs (Extended Data Fig. 5h ) 22 . WT cells showed an increase in MRE11 and RAD51 association with stalled RFs (Fig. 3f ). Ptip-deficient cells also showed an increase in RAD51 association at RFs, but MRE11 association with nascent DNA was reduced upon HU treatment ( Fig. 3f ), consistent with our immunofluorescence analysis ( Fig. 3c and Extended Data Fig. 5f ). Thus, MRE11 deposition on newly synthesized DNA is dependent on PTIP, which itself is recruited to stalled forks upon HU treatment (Extended Data Fig. 5i ) 22 . Fig. 5g . f, iPOND analyses of proteins at replication forks (capture). Input represents 0.25% of the total cellular protein content. RAD51 and MRE11 levels (shown below) were normalized to total H3. Experiments were repeated three times.
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PTIP is also known to constitutively associate with PA1 and with MLL3/MLL4 histone methyltransferases which catalyse methylation of histone H3 at lysine 4 (refs 23, 24) . To identify the region of PTIP that promotes RF degradation in Brca2-deficient cells, we expressed EV (empty vector), FL (full-length PTIP), W165R (disrupting interactions with PA1) 25, 26 , W663R (disrupting interactions with 53BP1 at DSBs) 25 or Del-BRCT5-6 (disrupting interaction with MLL3/4 independently of DSBs) 23, 24, 26 in Brca2/Ptip doubly deficient cells. We observed that only reconstitution of Brca2/Ptip-deficient cells with PTIP-Del-BRCT5-6 maintained fork protection (Extended Data Fig. 6a ).
We therefore tested whether the recruitment of MRE11 at stalled forks was dependent on MLL3/4. We observed that MRE11 association at RFs was dependent on MLL3/4 as monitored by iPOND and immunofluorescence analysis (Extended Data Fig. 6b, c) . We also observed an enrichment of H3K4me1 and H3K4me3 at nascent forks upon HU treatment that was PTIP-and MLL3/4-dependent ( Fig. 3f and Extended Data Fig. 6b ). Thus, deposition of MRE11 on newly synthesized or stalled chromatin correlates with the establishment of H3K4me1 and H3K4me3 at RFs.
To determine whether MLL4 contributes to degradation of stalled forks in Brca-deficient cells, we examined RF degradation in Brca1 −/− Mll4 −/− and Brca2 −/− Mll4 −/− B cells. Brca1 −/− Mll4 −/− and Brca2 −/− Mll4 −/− cells displayed a partial rescue of fork degradation (Extended Data Fig. 6d, e ). To test whether MLL4 methyltransferase activity is critical, we targeted the catalytic SET domain of MLL4 in Brca1-deficient B cells. We observed a significant rescue of fork degradation in Brca1 −/− Mll4-SET −/− cells, suggesting that the methyltransferase activity is important for promoting fork degradation (Extended Data Fig. 6f ).
RF protection confers chemoresistance
RF protection contributes to genome stability in a manner independent of DSB-induced HR 2,3,5 . Consistently, we observed that Brca2 −/− Mll4 −/− B cells showed a partial rescue of chromosomal aberrations upon PARPi and cisplatin treatment compared with Brca2 −/− cells alone (Extended Data Fig. 6g ). However, Rif1-deficient cells, characterized by extensive RF degradation ( Fig. 1c ) but normal irradiationinduced RAD51 foci formation (Extended Data Fig. 7a ), showed increased chromosomal aberrations in response to replication poisons PARPi, HU and cisplatin (Extended Data Figs 3a and 7b , c) 27 . We therefore speculated that RF stability mediated by loss of PTIP ( Fig. 1d, e ) might confer genome stability to Brca-deficient cells exposed to chemotherapeutics that poison DNA replication. Indeed, we found that Ptip deficiency reduced the levels of chromosomal aberrations both in Brca1 −/− and in Brca2 −/− B cells (Fig. 4a, b) .
To test whether differential levels of PTIP expression could be an indicator of patient responses to platinum chemotherapy, we queried clinical information from The Cancer Genome Atlas (TCGA) of patients with Brca1/Brca2-mutated ovarian serous adenocarcinoma treated with platinum chemotherapy (Extended Data Fig. 8a, b) . Survival analysis demonstrated that platinum-treated Brca2 mutants with high PTIP expression were correlated with a longer progressionfree survival (PFS) (Extended Data Fig. 8a ). Lower expression of PTIP also predicted a shorter PFS in Brca2-associated ovarian cancers (Extended Data Fig. 8b ). Taken together, these data suggest that PTIP levels could be a biomarker for acquired resistance to platinum-based chemotherapy in Brca1/2-mutated ovarian cancers.
An unbiased shRNA screen recently demonstrated that reduced levels of the nucleosome remodelling factor CHD4 in Brca2 mutant cancers correlated with poor patient response to chemotherapy, and increased tolerance to DNA-damaging agents without restoration of RAD51-dependent HR 28 . To test whether the resistance mechanism in this case occurs through RF protection, we knocked down CHD4 in the Brca2 mutant ovarian cancer cell line PEO1 (Extended Data Fig. 8c, d) . While CHD4 depletion in Brca2 mutant cells did not restore HR 28 , we observed that it largely conferred protection to nascent replication tracts from degradation upon HU treatment (Fig. 4c) .
Moreover, depletion of CHD4 resulted in significantly decreased recruitment of MRE11 upon HU treatment in Brca2 mutant cells (Extended Data Fig. 8e, f) .
These results suggest that MRE11-mediated degradation contributes to genome instability upon treatment with replication poisons. To test this idea, we pre-incubated Brca2-deficient B cells with the MRE11 nuclease inhibitor mirin before treating with PARP inhibitor or cisplatin. Mirin treatment did not alter the frequency of replicating cells monitored by EdU incorporation (Extended Data Fig. 8g ). However, incubation with mirin reduced the levels of PARPi-induced chromosomal aberrations approximately twofold. Similarly, Brca2-deficient cells were partly protected from cisplatin-induced DNA damage when MRE11 nuclease activity was inhibited (Extended Data Fig. 8h ). . Experiments were repeated four times. c, Ratio of IdU versus CldU in BRCA2-mutated PEO1 cells either mock (shNSC) infected or infected with shRNA against CHD4 (shCHD4) (*P ≤ 0.05, ****P ≤ 0.0001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed. d, Ratio of IdU versus CldU in HU-treated B cells (*P ≤ 0.05, ****P ≤ 0.0001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed. e, Genomic instability in B cells (n = 50; ***P ≤ 0.001, unpaired t-test). Experiments repeated four times. f, g, Kaplan-Meier survival curves in mice implanted with either PARPi-naive or -resistant tumours and treated with either topotecan (f) or cisplatin (g) using log-rank (Mantel-Cox) test. h, Ratio of IdU versus CldU in untreated or HU-treated tumours (PARPi naive versus PARPi resistant) (****P ≤ 0.0001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed.
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We conclude that MRE11 nuclease promotes genomic instability in Brca2-deficient cells.
Since PARP1 (ARTD1) is required for MRE11 localization to stalled replication forks 29 and its loss rescues the embryonic lethality in Brca2null ESCs 30 , we tested the contribution of PARP1 to RF stability and genome integrity by generating Brca1 −/− Parp1 −/− B cells (Brca1 f/f ; Parp1 −/− ; Cd19Cre). Interestingly, loss of Parp1 protected Brca1deficient RFs from degradation and resulted in a significant reduction in chromosomal aberrations (Fig. 4d, e ). Nevertheless, Parp1 deficiency failed to rescue irradiation-induced RAD51 foci formation in Brca1-deficient cells (Extended Data Fig. 8i ). Thus, despite the fact that treatment with PARP inhibitor increases levels of DNA damage in Brca1-deficient cells 31, 32 , loss of Parp1 before Brca1 loss protects against genome instability.
To determine whether Brca2-deficient tumour cells acquire chemotherapy resistance via RF protection, we induced PARPi-resistance using the KB2P mouse model for Brca2-deficient breast cancer (Extended Data Fig. 9a) 33 . A mammary tumour from KB2P mice was transplanted into syngeneic FVB mice and, when the tumour reached a size >200 mm 3 , mice were treated with PARPi (AZD2461) for 28 consecutive days (Extended Data Fig. 9b, c) . The tumour was initially responsive to treatment but eventually grew, upon which treatment was repeated until PARPi resistance was achieved (Extended Data Fig. 9c ). The stability of acquired resistance was confirmed by re-transplanting matched naive and resistant tumours and treating the animals with vehicle or AZD2461 (Extended Data Fig. 9d ). PARPi-resistant tumours also showed cross-resistance to replication poisons topotecan and cisplatin (Fig. 4f, g) .
Both naive and resistant Brca2-deficient tumours showed impaired irradiation-induced RAD51 foci formation (Extended Data Fig. 9e, f) . We therefore assayed naive and resistant tumours ex vivo for RF stability. The mean length of the CldU and the IdU tracts were similar in all samples that were not treated with HU ( Fig. 4h and Extended Data Fig. 9g ). While naive tumour cells showed degradation of nascent tracts upon HU treatment, resistant tumour cells were protected (Fig. 4h) . These data suggest that RF protection rather than restoration of HR may be the main mechanism for acquired resistance in this mammary tumour. However, in this case, acquired resistance was not simply due to loss of PTIP or MRE11 proteins (Extended Data Fig. 9h ).
Discussion
Our study and the accompanying paper 30 provide the first examples of genetic alterations that bypass the essential requirement for DSBinduced HR, evidenced by the finding that reduction in PTIP or PARP1 (ARTD1) levels rescues the lethality of Brca2-null ESCs. We speculate that the reason Brca2 nullizygosity is compatible with viability is because RAD51 is able to perform essential HR functions (such as SCE) by loading onto RFs independently of BRCA2 (Extended Data Fig. 4e ), even if RAD51 loading onto processed DSBs is strictly dependent on BRCA2 ( Fig. 1g and Fig. 2c, d) . We also show that loss of PTIP, PARP1 and CHD4 confers resistance to a variety of DNA-damaging agents in Brca-deficient cells. Resistance to PARPi and cisplatin both in primary and in tumour cells grown in vitro or in vivo correlates with protection from RF degradation. While 53BP1 disruption rescues the viability of Brca1-deficient mice by restoration of HR 8, 9 , cells from these animals show residual levels of chromosomal aberration. The significant level of RF degradation observed in Brca1 −/− 53Bp1 −/− cells (Fig. 1b ) may contribute to this genome instability.
Since RF degradation is mediated by MRE11, we propose that persistence of MRE11 at stalled forks is toxic and normally counteracted by BRCA1/2. One possibility is that MRE11 could initially be recruited to stalled forks to mediate RF restart 4 , and that BRCA1/2 is necessary to subsequently disengage MRE11 from already-processed DNA termini. Consistently, we have found a significant increase in chromatin-bound MRE11 in Brca2-deficient cells treated with HU or cisplatin (Extended Data Fig. 10 a, b) 4 . In Saccharomyces cerevisiae, failure to remove MRE11 from single-stranded DNA can lead to hypersensitivity to a variety of clastogens 34, 35 . We therefore propose that deficiencies in PTIP, CHD4 and PARP1 could confer drug resistance in Brcadeficient cells by limiting the access of MRE11 to single-strand DNA at stalled RFs.
In summary, we have shown that protection of nascent DNA from degradation provides a mechanism that can promote synthetic viability and drug resistance in Brca-deficient cells without restoring HR at DSBs.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Resting splenic B cells were isolated from 8-to 12-week-old WT or mutant spleen with anti-CD43 microbeads (anti-Ly48; Miltenyi Biotech) and were cultured with LPS (25 μg/ml; Sigma), IL-4 (5 ng/ml; Sigma) and RP105 (0.5 μg/ml; BD) as described 10 . Stimulated B cells were additionally infected with CRE to ensure a high level of gene deletion in these cells. All mice were randomly distributed in experimental groups after genotyping. WT MEFs were immortalized by SV40 retroviral infection, and SV40 immortalized Ptip f/f (ref. 39) and Mll3 −/− Mll4 f/f MEFs 38 were infected with a CRE retrovirus to delete Ptip and Mll4 respectively. Coding sequences for mouse Ptip-GFP were cloned into the MIGR1 retroviral vector as previously described 10 . All cell lines used were tested for mycoplasma using a Mycoplasma Detection Kit (Invitrogen) and relevant cell lines were authenticated either by genotyping or western blot analysis. PARP inhibitor (KU58948) was obtained from AstraZeneca. Mirin was obtained from Sigma, PFM39 and WRN inhibitors were gifts from J. Tainer and R. Brosh respectively. DNA2 inhibitor has been described 40 . Cisplatin and HU were obtained from Sigma. For FISH analysis, metaphases were prepared and imaged as described 10 . Animal experiments were approved by the Animal Care and Use Committee of NCI-Bethesda and the Animal Ethical Committee of The Netherlands Cancer Institute. Generation of CHD4-deficient PEO1 lines using RNAi. BRCA2-mutated ovarian cancer cell lines PEO1 were grown in DMEM with 10% FBS and 1% Glutmax. RNAi for CHD4 was performed as previously described 28 . ESC lines, shRNA knockdowns and rescue of BRCA2 viability. PL2F2 mouse ESCs were maintained in M15 media (Knockout DMEM with 15% fetal bovine serum, 0.00072% β-mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin and 0.292 mg/ml l-glutamine) at 37 °C, 5% CO 2 . ESCs were plated on a monolayer of mitotically inactive feeder cells as described previously 17 . BRCA2 conditional knockout ESCs were generated as previously described 17 . Two different shRNAs against Ptip mRNA were cloned into pSuperior vector (Oligoengine). shRNA sequences are listed below with the targeted sequences underlined: mPtip shRNA-1 sense, 5′GATCCCC GTGGCGCTCTCCTGCCAGT TTCAAGAGA ACTGGCAGGAGAGCGCCAC TTTTTA 3′; mPtip shRNA-1 antisense, 5′ AGCTTAAAAA GTGGCGCTCTCCTGCCAGT TCTCTTGAA ACTGGCAGGAGAGCGCCAC GGG 3′; mPtip shRNA-2 sense, 5′GATCCCC CCGTAGCAACACAGTCCTC TTCAAGAGA GAGGACTGTGTTGCTACGG TTTTTA 3′; mPtip shRNA-2 antisense, 5′ AGCTTAAAAA CCGTAGCAACAC AGTCCTC TCTCTTGAA GAGGACTGTGTTGCTACGG GGG 3′.
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METHODS
shRNA vectors were linearized by ScaI and electroporated into ESCs using a Bio-Rad gene pulser. Cells were selected in G418 (0.18 mg/ml) 24 h after electroporation for 5 days. Individual colonies were picked and PTIP levels were determined by western blotting. The PGK-Cre plasmid was electroporated into Ptip shRNA knockdown cells (20 μg DNA for 1 × 10 7 cells). Thirty-six hours after electroporation, HAT (hypoxanthine-aminopterin-thymidine) selection was performed for 5 days, after which cells were switched to HT (hypoxanthine-thymidine) media for 2 days and then transferred to normal media. Colonies were picked when visible, genomic DNA was extracted and Southern blotting was performed as described previously 17 . For PCR genotyping, the following primers were used to amplify the Brca2 cko allele and Brca2-KO allele: Brca2-KO forward, 5′ GCCACCTCTGCCTGATTCTA; Brca2-KO reverse, 5′ AAAGAACCAGCTGGGGCTCGAG; Brca2-flox forward, 5′ TG AAGTGGACCCTGTAACCC; Brca2-flox reverse, 5′ AGTTCTCTCCTTTCA GCCTTCT. Gene targeting and the gene conversion HR assay. For gene targeting, ESCs were electroporated with 75 μg of linear targeting fragment from p59xDR-GFP, followed by selection for 5 days in 110 μg/ml hygromycin; then they were allowed to grow in normal ESC media 36 . Colonies were picked, and targeted clones were identified by Southern hybridization as described 36 . For the DSB-induced HR assay, ESCs were transiently electroporated with 20 μg of either pDR-GFP only or pDR-GFP plus I-SceI expressing vectors for 48 h. Gene conversion was read-out as the percentage of GFP-positive cells by flow cytometry analysis 41 . DNA fibre analysis. Asynchronous B cells, BRCA2-mutated PEO1 cells and Brca2-deficient K2BP tumours were labelled with 30 μM CldU, washed with PBS and exposed to 250 μM IdU. After exposure to IdU, the cells were washed again in warm PBS and treated or not with HU before collection. Cells were then lysed and DNA fibres stretched onto glass slides, as described 42 . The fibres were denatured with 2.5 M HCl for 1 h, washed with PBS and blocked with 2% BSA in phosphate buffered saline Tween-20 for 30 min. The newly replicated CldU and IdU tracts were revealed with anti-BrdU antibodies recognizing CldU and IdU respectively. Images were taken at 60 × magnification (Zeiss Axio Observer.Z1), and statistical analysis was performed using GraphPad Prism. DSB detection by PFGE. DSB detection by PFGE was done as described 42 . Ethidium-bromide-stained gels were analysed using an UVP EC3 imaging system. Quantification was performed using ImageJ normalizing DSB signals to unsaturated DNA signals in the well. Relative DSB levels were obtained by comparing treatment results to the background DSB signals observed for untreated conditions. Western blotting and immunofluorescence. Primary antibodies were used at the following dilutions: anti-tubulin (1:15,000, Sigma), anti-H3K4me3 (1:5,000, Millipore), anti-H3K4me1 (1:5,000, Millipore), anti-RAD51 (1:50, Santa Cruz), anti-PCNA (1:2,000, Santa Cruz), anti-total H3 (1:1,000 Millipore) and anti-Mre11 (1:10,000, gift from J. Petrini, MSKCC). MEFs were prepared for immunofluorescence by growth on 18 mm × 18 mm glass cover slips. Lymphocytes were dropped onto slides coated with CellTak (BD Biosciences). Cells were fixed with methanol and incubated with primary antibody as indicated. iPOND and flow cytometry. iPOND was performed essentially as described 22 . One hundred and fifty million WT, Ptip −/− and Mll3 −/− Mll4 −/− MEFs were labelled with 10 μM EdU (Life Technologies) and treated with HU as indicated. Two hundred million cells were use for iPOND experiments with ESCs. Cells were cross-linked with 1% formaldehyde for 10 min at room temperature, quenched with 0.125 M glycine and washed with PBS. For the conjugation of EdU with biotin azide, cells were permeabilized with 0.25% Triton X-100/ PBS, and incubated in click reaction buffer (10 mM sodium-l-ascorbate, 20 μM biotin azide (Life Technologies), and 2 mM CuSO4) for 2 h at room temperature. Cells were resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, and 1% SDS) supplemented with protease inhibitors (Roche), and chromatin was solubilized by sonication in a Bioruptor (Diagenode-Pico) at 4 °C for 24 min. After centrifugation, clarified supernatants were incubated for 1 h with streptavidin-MyOne C1 beads (Life Technologies). Beads were washed and captured proteins were eluted by boiling beads in 2 × NuPAGE LDS Sample Buffer (Life Technologies) containing 200 mM DTT for 40 min at 95 °C. Proteins were resolved by electrophoresis using NuPAGE Novex 4-12% Bis-Tris gels and detected by western blotting with the indicated antibodies. For flow cytometric analysis, asynchronous B cells were pulsed with 10 mM EdU for 20 min at 37 °C and stained using the Click-IT EdU Alexa Fluor 488 Flow Cytometry Assay Kit according to the manufacturer's specifications (ThermoFisher C-10425). Generation of AZD2461-resistant KB2P tumours and in situ RAD51 assay. Brca2 −/− ;p53 −/− mammary tumours were generated in K14-cre;Brca2 f/f ; p53 f/f (KB2P) female mice and genotyped as described previously 33 . Orthotopic transplantations into WT FVB/N/OLA (F1) mice, tumour monitoring, and sampling were conducted as described 43 . Starting from 2 weeks after transplantation, tumour size was monitored at least three times a week. All treatments were started when tumours reached a size of approximately 200 mm 3 . AZD2461 (100 mg/kg) was given orally for 28 consecutive days. If tumours did not shrink below 100% of the initial volume, treatment was continued for another 28 days. AZD2461 was diluted in 0.5% w/v hydroxypropyl methylcellulose in deionized water to a concentration of 10 mg/ml. For testing cross-resistance, mice were given a single treatment regimen of topotecan (2 mg/kg intraperitoneally, days 0-4 and 14-18) or cisplatin (Mayne Pharma, 6 mg/kg intravenously, day 0). Statistical analysis was performed using GraphPad Prism (log-rank Mantel-Cox test). The in situ RAD51 irradiation induced formation assay has been described 44 . Statistics. Statistics was performed by two-tailed t-test, Mann-Whitney test or by log-rank Mantel-Cox test unless otherwise specified. Statistical tests were justified appropriate for every figure. The data were normally distributed and the variance between groups being statistically compared was similar. No statistical methods or criteria were used to estimate sample size or to include/exclude samples. The investigators were not blinded to the group allocation during the experiments; however, the samples were coded before analysis unless otherwise specified.
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Extended Data Figure 1 | Fork degradation in Brca-deficient B lymphocytes is mediated by MRE11 exonuclease activity. a, b, Ratio of IdU versus CldU upon HU treatment in WT, Brca1 −/− (a) and WT, Brca2 −/− (b) B lymphocytes with or without mirin pre-treatment. Numbers in red indicate the mean ± s.d. for each sample (**P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed for each genotype. c, Ratio of IdU versus CldU upon HU treatment in Brca2 −/− B lymphocytes with or without mirin, PFM39 (MRE11 exonuclease inhibitor), PC5 (DNA2 inhibitor) or WRNi pre-treatment. Numbers in red indicate the mean ± s.d. for each sample (**P ≤ 0.05, ****P ≤ 0.0001, Mann-Whitney test). One hundred and twenty-five replication forks were analysed for each genotype.
It has come to our attention that in this Article, owing to an error during the production process, 'Brca2' was mislabelled as 'Brca1' in Fig. 4b , and 'Parp1' was mislabelled as 'Ptip' in Fig. 4e . These errors have been corrected in the online versions of the paper.
CORRECTIONS & AMENDMENTS
